A chloroquinoline derivate presents effective in vitro and in vivo antileishmanial activity against Leishmania species that cause tegumentary and visceral leishmaniasis. (December 2019)

• Record Type: Journal Article
• Authors: Sousa, Jessica K.T.; Antinarelli, Luciana M.R.; Mendonça, Débora V.C.; Lage, Daniela P.; Tavares, Grasiele S.V.; Dias, Daniel S.; Ribeiro, Patrícia A.F.; Ludolf, Fernanda; Coelho, Vinicio T.S.; Oliveira-da-Silva, João A.; Perin, Luísa; Oliveira, Bianka A.; Alvarenga, Denis F.; Chávez-Fumagalli, Miguel A.; Brandão, Geraldo C.; Nobre, Vandack; Pereira, Guilherme R.; Coimbra, Elaine S.; Coelho, Eduardo A.F.
• Is Part Of: Parasitology international. Volume 73(2019)
• Publication Date: 2019-12
• Subjects: Antileishmanial activity -- Chloroquinoline derivate -- Treatment -- Leishmaniasis -- Toxicity -- Mammalian hosts; Parasitology -- Periodicals; Parasites -- Periodicals; Parasitic Diseases -- Periodicals; Parasitology -- Periodicals; Parasitologie -- Périodiques; 571.99905
• DOI: 10.1016/j.parint.2019.101966
• Languages: English
• ISSNs: 1383-5769

Abstract

Abstract : Abstract: The identification of new therapeutics to treat leishmaniasis is desirable, since available drugs are toxic and present high cost and/or poor availability. Therefore, the discovery of safer, more effective and selective pharmaceutical options is of utmost importance. Efforts towards the development of new candidates based on molecule analogs with known biological functions have been an interesting and cost-effective strategy. In this context, quinoline derivatives have proven to be effective biological activities against distinct diseases. In the present study, a new chloroquinoline derivate, AM1009, was in vitro tested against two Leishmania species that cause leishmaniasis. The present study analyzed the necessary inhibitory concentration to preclude 50% of the Leishmania promastigotes and axenic amastigotes (EC50 value), as well as the inhibitory concentrations to preclude 50% of the murine macrophages and human red blood cells (CC50 and RBC50 values, respectively). In addition, the treatment of infected macrophages and the inhibition of infection using pre-treated parasites were also investigated, as was the mechanism of action of the molecule in L. amazonensis . To investigate the in vivo therapeutic effect, BALB/c mice were infected with L. amazonensis and later treated with AM1009. Parasitological and immunological parameters were also evaluated. Clioquinol, a known antileishmanial quinoline derivate, and amphotericin B (AmpB), were used as molecule and drug controls, respectively. Results in both in vitro and in vivo experiments showed a better and more selective action of AM1009 to kill the in vitro parasites, as well as in treating infected mice, when compared to results obtained using clioquinol or AmpB. AM1009-treated animals presented significantly lower average lesion diameter and parasite burden in the infected tissue and organs evaluated in this study, as well as a more polarized antileishmanial Th1 immune response and low renal and hepatic toxicity. This result suggests that AM1009 should be considered a possible therapeutic target to be evaluated in future studies for treatment against leishmaniasis. Graphical abstract: Unlabelled Image Highlights: A new chloroquinoline derivative, AM1009, was tested against Leishmania parasites. The molecule was in vitro effective against axenic amastigotes and promastigotes. AM1009 caused low toxicity in two types of mammalian cells. The mechanism of action was based on apoptosis/necrosis of the parasites. In vivo experiments showed effective action to treat against L. amazonensis infection.